$LUNG

French Glendon E. III sold $21K of LUNG

French Glendon E. III (President and CEO) sold 13,511 shares of Pulmonx Corp (LUNG) at $1.57 on 2026-06-02.

Original reporting
SEC EDGAR · French Glendon E. III
Published Jun 3, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LUNG
Neutral
medium confidence
Mentioned
$LUNG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

Traders may briefly reassess sentiment toward LUNG, but without new fundamentals the signal is typically low-conviction.

02

Market read

A CEO open-market sale is disclosed; it may modestly pressure sentiment but is unlikely to drive a durable repricing alone.

03

What to watch

No 10b5-1 plan is indicated, but the filing also lacks context (taxes, diversification, planned expenses) that often drives Form 4 sales.

Relevance 6/10Novelty 6/10Timing: Filed today; transaction dated 2026-06-02 (after market close).

Background

SEC Form 4 reports insider transactions by officers/directors; this one is an open-market sale by the CEO.

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

Pulmonx CEO French Glendon E. III sold 13,511 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional disclosures.

Evidence & confidence

The filing is an ownership-change disclosure with no stated reason, no 10b5-1 plan, and no accompanying fundamental news.

Market effects

Minimal; this is company-specific insider activity without sector-wide information.

None.

None.

Counterpoint

The sale could be routine liquidity/portfolio management rather than a bearish view, especially without any accompanying negative news.

Key entities

  • Pulmonx Corp

    Subject of the insider transaction disclosure (LUNG).

  • French Glendon E. III

    President and CEO who sold 13,511 shares at $1.57 on 2026-06-02.

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu